Treatment of Pancreatic Adenocarcinoma by Combining Contrast Agent and Gemitabine Under Sonification
- Patients with inoperable pancreatic cancer (ICD-10 C25.0-3) at the Department of
Surgical Gastroenterology of Haukeland University Hospital, who have volunteered to
- Patient participated in an investigational study within 30 days prior to study entry
(or, if longer, within five half-lives of the last dose of any investigational drug).
- Patient has severe chronic obstructive pulmonary disease or severe chronic asthma.
- Patient has a history of cardiovascular ischemia, acute myocardial infarction or
unstable angina within 3 months prior to study entry.
- Patient has a history of any psychiatric disorder or cognitive impairment that would
interfere with participation in the study.
- Patient has a known history of Hepatitis B, Hepatitis C or HIV infection.
- Patient requires dialysis or has severely impaired renal function, defined as a serum
creatinine > 180 mmol/L at the Screening Visit.
- Patient has severe impairment of liver function, defined as a serum albumin level ≤
25 g/L and/or a Protrombin Time INR > 2.3 (or APTT > 6 seconds above the upper limit
of normal) at the Screening Visit.
- Patient is pregnant or is breast-feeding.
- Patient is allergic to or intolerant of gemcitabine
- Patient is allergic to or intolerant of SonoVue® BRACCO ultrasound contrast agent
- Any reason why, in the opinion of the investigator, the patient should not